Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: inflammation, other_emerging
- Who it enrolls
- age 18 Years to no upper limit; BMI ≥27 required; conditions: Obesity and Overweight; HIV; Chronic Inflammation
- Interventions
- Tirzepatide
- Conditions
- Obesity and Overweight; HIV; Chronic Inflammation
- Phase and size
- Phase 2 · 12 participants
- Dates
- Start 2025-11-12
Primary completion 2026-06-02 - Sponsor
- University of Hawaii (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change in Baseline Body Weight12 weeks
02Eligibility
Who can take part
Age ≥ 18 years HIV-1 infection (well controlled) * Documented HIV-1 infection ≥ 1 year prior to study entry (ELISA confirmed by Western blot or HIV-1 RNA) AND * HIV-1 RNA \<200 copies/mL for ≥ 6 months Stable ART · Receiving a stable antiretroviral regimen for at least 1 year prior to study entry Overweight * BMI ≥27 kg/m2 plus at least one weight-related condition (defined as a medical history of dyslipidemia, hypertension, cardiovascular disease, or obstructive sleep apnea) OR Obese * BMI ≥ 30 kg/m2
03Change log
Registry changes
No changes recorded since the trial was added.